Munich (Germany), November 13, 2017: ImevaX GmbH, a specialist in rapid diagnostic tests and vaccines against pathogens of chronic infectious diseases, announces today the completion of a EUR 1.25 million Series A-2 financing round. The round was led by Wellington Partners. Co-lead investors were BioMedPartners with their BioMedInvest-II LP fund, Santo Venture Capital and KfW. ImevaX is a 2014 spin-out from the Technische Universität München (TUM) and has been recently awarded a EUR 5.9 million financing from the GO-Bio Phase II program of the Federal Ministry of Education and Research (BMBF).
The funds will be used to finalize the clinical study phase 1for the lead candidate IMX 101 before partnering and to develop a rapid diagnostic test for Helicobacter pylori (H. pylori) .
Dr. Marie Roskrow, Chief Executive Officer of ImevaX GmbH since September 15, 2015 commented: “The continued support of our investors will allow to finish the clinical study phase 1 for our vaccine and start to develop our first rapid diagnostic test to create value for the company.”
ImevaX is a biopharmaceutical company founded in 2014 based in Munich, Germany. The focus is to combat chronic and nosocomial infections by creating specific vaccines and develop new generations of rapid diagnostic tests.
About Wellington Partners
Wellington Partners is one of the most successful pan-European venture capital firms. With some EUR 850 million under management and offices in London, Munich, Palo Alto and Zurich, the firm invests into companies throughout Europe that have the potential to become global leaders in the areas of Life Sciences, Digital Media and Software. Since 1998, Wellington Partners has invested in more than 100 European companies, including now publicly traded Actelion, Evolva, Genticel, Implanet, Oxford Immunotec, Supersonic Imagine and privately held companies like AyoxxA, immatics, invendo medical, MPM Medical, MTM Laboratories (acquired by Roche), NEUWAY Pharma, Oxagen, Rigontec, Quanta, Sapiens (acquired by Medtronic), Sensimed and Symetis.
BioMedPartners AG is an independent healthcare-dedicated investment firm based in Basel, Switzerland, that provides private equity and mezzanine financing to private early- to mid-stage healthcare and life science companies in Switzerland and neighboring regions (Alpine Rim). BioMedPartners have over CHF 250 million under management and have invested in or given loans to 45 companies, including now publicly traded Affimed, Arpida, Evolva and Santhera and the exited privately held companies Glycart Biotechnologies (acquired by Roche), ESBATech (acquired by Alcon/Novartis), Activaero (acquired by Vectura) and Okairos (acquired by GSK). BioMedPartners currently invest out of their BioMedInvest II LP fund, which has a size of CHF 106 million, and was closed in 2009.
About EMBL Ventures
EMBL Ventures is an independent venture capital investor that manages two funds with a total of EUR 68 million capital on behalf of major European institutional and private investors. EMBL Ventures’ close relationship with the European Molecular Biology Laboratory (EMBL) and its technology transfer organization EMBL Enterprise Management Technology Transfer GmbH (EMBLEM) allows it to finance disruptive technologies in an entrepreneurial start-up environment, aiming ultimately for a transaction with a partner that is seeking to acquire external product innovation. EMBL Ventures is exclusively focused on life-science investments.
About Santo Venture Capital
Santo Venture Capital is the venture arm of ATHOS Service GmbH, the Family Office of the Strüngmann family.
For further information, please contact:
Chief Financial Officer
Tel: +49 (0) 89-41 424 55-0